Document


 
 
 
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
___________________________
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  January 7, 2019
 
___________________________
 
ACCELERON PHARMA INC.
(Exact name of Registrant as specified in its charter)
 

Delaware
(State or other jurisdiction
of incorporation)
 
001-36065
(Commission
File Number)
 
27-0072226
(I.R.S. Employer
Identification Number)
 
 
 
 
 
128 Sidney Street
Cambridge, MA
 (Address of principal
executive offices)
 
 
 
02139
(Zip Code)
 
Registrant’s telephone number, including area code:  (617) 649-9200
 
Not Applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company            o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.            o
 
 
 
 
 




Item 7.01    Regulation FD Disclosure.
 
Acceleron Pharma Inc. (the "Company") intends to participate in investor meetings at the 37th Annual J.P. Morgan Healthcare Conference (the "Conference") during the week of January 7, 2019, and intends to present an overview of the Company along with its corporate priorities at the Conference on January 7, 2019.

The slide presentation to be used in investor meetings and presented at the Conference is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The furnishing of the attached slide presentation is not an admission as to the materiality of any information therein. The information contained in the slides is summary information that is intended to be considered in the context of more complete information included in the Company's filings with the Securities and Exchange Commission and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate.

The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or for any other purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in any such filing, except as expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits.
 
(d)    Exhibits.
 
Exhibit Number
 
Description of Exhibit
99.1
 


2



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
ACCELERON PHARMA INC.
 
 
 
 
 
By:
/s/ John D. Quisel, J.D., Ph.D.
 
 
John D. Quisel, J.D., Ph.D.
 
 
Executive Vice President and Chief Business Officer
 
 
 
January 7, 2019
 
 


3
xlrn20190107form8kex991
Exhibit 99.1 Corporate Presentation January 7, 2019 1


 
Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY’S STRATEGY, FUTURE PLANS and prospects, including statements regarding the development of the Company's compounds, the timeline for clinical development and regulatory approval of the Company’s compounds and the expected timing for reporting of data from ongoing clinical trials. The words “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE INCLUDED IN THE FORWARD-LOOKING STATEMENTS DUE to various factors, risks and uncertainties, including, but not limited to, that preclinical testing of the Company's compounds and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that the results of any clinical trial may not be predictive of the results or success of other clinical trials of the same product candidate, that the development of the Company's compounds will take longer and/or cost more than planned, that the Company will be unable to successfully complete the clinical development of the Company’s compounds, that the Company may be delayed in initiating, enrolling or completing any clinical trials, and that the Company's compounds will not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading "Risk Factors" included in the Company's most recent Annual Report on Form 10-K, and other filings that the Company has made and may make with the SEC in the future. THE FORWARD-LOOKING STATEMENTS CONTAINED IN THIS PRESENTATION ARE BASED ON MANAGEMENT’S CURRENT views, plans, estimates, assumptions and projections with respect to future events, and the Company does not undertake and specifically disclaims any obligation to update any forward-looking statements. 2


 
Mission and Therapeutic Area Focus HEMATOLOGY Our mission is to transform the lives NEUROMUSCULAR of patients with serious and rare diseases PULMONARY 3


 
Building Therapeutic Area Leadership HematologyHHematollogy HEMATOLOGY NEUROMUSCULAR PULMONARY LuspaterceptLusppaterceptp Phase 3 Trials--Luspatercept Phase 2 Trials Phase 2 Trials--Sotatercept Lower-Risk MDS, RS+ ACE-083 Facioscapulohumeral muscular dystrophy (FSHD) Pulmonary arterial hypertension (PAH) ɴ-Thalassemia, Transfusion-Dependent ACE-083 Charcot-Marie-Tooth disease (CMT) Lower-Risk MDS, First-line Exploratory trial in PAH Phase 2 Trials Phase 1 Trial Preclinical ACE-2494 ACE-1334 ɴ-Thalassemia, Non-Transfusion-Dependent Healthy volunteers Pulmonary disease MDS / ɴ-Thalassemia / MF FSHD / CMT PAH 4


 
2018 Key Milestones Across Therapeutic Areas Luspatercept ACE-083 Sotatercept Positive MEDALIST and BELIEVE Positive Part 1 results in CMT and PULSAR Phase 2 trial initiated Phase 3 trial results FSHD Phase 2 trials Multiple preclinical presentations ASH 2018 – MEDALIST and Presentations at multiple medical at AHA BELIEVE presentations selected congresses for “Best of ASH” SPECTRA exploratory trial planned Part 2 of each Phase 2 trial COMMANDS and BEYOND trials initiated initiated 5


 
Anemia impacts approximately 25%1 of the population, or >1.5b people worldwide Hematology 1. de Benoist B et al., eds. Worldwide prevalence of anaemia 1993-2005. WHO Global Database on Anaemia Geneva, World Health Organization, 2008


 
Chronic Anemia Due to Rare Blood Disorders LOWER-RISK MDS Bone marrow failure disorder BETA-THALASSEMIA CHRONIC Genetic hemoglobin mutation ANEMIA MYELOFIBROSIS Fibrotic bone marrow disease 7


 
Anemia’s Impact on Patients Fatigue/tiredness/weaknessdness/weakness Shortness off breathbreath/dizziness/dizziness Reduced mentalntal sharpnesssharpness Impact on dailyaily activitactivityy level Regular red bbloodlood cell transfusions 8


 
Burden of Red Blood Cell Transfusion Process Blood donation Processing, testing, Storage Distribution & packaging 6ම ĨŽƌчϰϮĚĂLJƐ Patient with chronic Red Blood Cell Iron Overload anemia hits Cross-match Transfusion Infection hemoglobin threshold Appointment Decreased Mortality Appointment Alloimmunization ~Every 2-3 Weeks 4 to 8 hours in center Economic Burden 9


 
Lack of Viable Treatment Options 1989 > 30 years 2020 Synthetic Potential erythropoietin No new product approvals to treat Luspatercept approved for lower-risk MDS-, beta-thalassemia-, and/or U.S. / E.U. market certain anemias myelofibrosis-associated anemia in the U.S. approval 10


 
Luspatercept: A First-in-Class Erythroid Maturation Agent 6WHP 3URJHQLWRU &HOO &HOOV (U\WKUREODVWPDWXUDWLRQLQWRUHGEORRGFHOOV TGF-BETA PROTEINS LUSPATERCEPT 11


 
MEDALIST and BELIEVE Phase 3 Trial Results Phase 3 Phase 3 Lower-Risk MDS, RS+ ɴ-Thalassemia, Transfusion-Dependent ƒ ASH 2018 plenary and oral presentations selected for “Best of ASH” ƒ Luspatercept met all primary and key secondary endpoints ƒ Durable responses with a favorable safety profile ƒ Planned U.S. and E.U. marketing application submissions in 1H:19 12


 
Additional Luspatercept Trials Underway Phase 3 Phase 2 Phase 2 Lower-Risk MDS, First-line ɴ-Thalassemia, Non- Transfusion-Dependent ƒ Enrolling up to 350 ƒ Enrolling up to 150 ƒ Enrolling up to 70 patients patients patients New trials supported by Phase 2 results 56%1 53%2 шϯϬй3 RBC Transfusion Independence Increase in Mean Hb шϭ͘ϬŐͬdL Anemia Response in Sotatercept Phase 2 IST3 1. EHA 2018: ESA naïve LR MDS patients, RBC-TI: 18/32 or 56% 13 2. ,ϮϬϭϴ͗EdƉĂƚŝĞŶƚƐ͕шϭ͘ϬŐͬdL, 16/30 or 53%, in weeks 13-24 fixed interval compared to 12 weeks pre-treatment 3. ASH 2017: sotatercept, monotherapy: 7/18 or 39% of evaluable patients; combination therapy: 3/10 or 30% of evaluable patients


 
A Potential Platform Treatment for Chronic Anemias Evaluating additional Lower-Risk MDS Lower-Risk MDS ɴ-Thalassemia ɴ-Thalassemia, diseases RS+ First-line Transfusion-Dependent Non-Transfusion- associated with Dependent anemia $2 Billion + $1 Billion + + TBD Estimated Estimated Annual Peak Annual Peak Sales Potential Sales Potential 14


 
Luspatercept’s Potential Revenue Drives Significant Value Acceleron Receives Royalty % Low to Mid-20s Celgene Funds Program Costs ~100% Potential Acceleron Annual Royalty Revenue Annual Peak Sales Potential Scenarios 15


 
Neuromuscular Disease


 
ACE-083: Targeting Focal Muscle Disease Administered into target Facioscapulohumeral Charcot-Marie-Tooth muscle for concentrated effect Muscular Dystrophy (FSHD) Disease (CMT) ACE-083 Myopathy Neuropathy Locally-acting ƒ 20,000 U.S. patients ƒ > 100,000 U.S. patients myostatin+ 17


 
High Unmet Medical Need in FSHD and CMT ƒ Slowly progressing muscle weakness diseases – Patients are typically diagnosed at a young age (20s to 30s) – Muscle weakness can progress asymmetrically ƒ No approved pharmacology solutions – Treatment is currently limited to physical therapy and bracing ƒ Foot drop (ankle weakness) affects a majority of patients leading to multiple challenges – Maintaining balance and frequent falls – Walking long distances and climbing up and down stairs ƒ Upper arm weakness (biceps) is reported in a majority of FSHD patients 18


 
Two-Part Phase 2 Trials in FSHD and CMT PART 1 RESULTS ƒ Mean total muscle volume increases (14% to 20%)* ƒ Reduction in absolute fat fraction (overall muscle quality improvement)* ƒ No serious adverse events, most common adverse events were mild or moderate (grades 1-2)* PART 2FSHD* OF EACH PHASE 2 TRIAL ONGOING FSHD Randomized 1:1 CMT Treatment Duration: N = 55 6 months N = 40 ƒ Primary Endpoint: target muscle volume increase (via MRI) ƒ Key Secondary Endpoints: functional walk and upper limb tests along with patient reported outcomes 19 *Part 1 of Phase 2 results: FSHD & CMT ACE-083 high dose cohorts as of WMS 2018 Meeting


 
Pulmonary Disease


 
Pulmonary Arterial Hypertension (PAH) Disease Background Symptoms PATIENT SNAPSHOT mean ƒ Shortness of breath age 50 ƒ Chest pain ƒ Dizziness and/or fainting 3 to 1 ƒ Exertion fatigue 70K women to men U.S./E.U. PAH Patients 21


 
Current Therapies Are Not Enough DRUG APPROVALS 14 disease modifying over the last 20 YEARS NO therapies Improved survival and quality of life Median survival ~5 to 7 years 22


 
PAH: A Disease of Vascular Remodeling Pulmonary Arteries Elevated pressure in the pulmonary circulation leads to heart failure Normal Arterial Hypertension • Smooth muscle cell hypertrophy • Endothelial cell proliferation • Intimal fibrosis 23


 
Sotatercept’s Activity in Preclinical Studies Sotatercept1 Preclinical Study: Sugen Hypoxia Model Lung histology Pulmonary Arterioles (10-50 μm, N=100) Classification (%)2 ;ɲ^DͬĞůĂƐƚŝŶƐƚĂŝŶŝŶŐ͕ϭϬyŵĂŐŶŝĨŝĐĂƚŝŽŶͿ % of Completely Muscularized Vessels 72.5% 29.3% Vehicle Sotatercept1 Vehicle Sotatercept1 1. RAP-011 24 2. Modified from Yu PB, Yung LM, Bocobo GA, Dinter T. ACTRIIA-Fc rebalances BMP and activin/TGF-beta signaling to attenuate experimental pulmonary hypertension. American Heart Association 2017 Scientific Sessions. November 14, 2017


 
PAH Phase 2 Trials Ongoing and Planned Traditional Phase 2 Trial Exploratory Phase 2 Trial Randomized, double blind, placebo-controlled Open-label, single arm N = 100 N = 25 6-month primary treatment period: 6-month primary treatment period endpoints: ƒ Primary endpoint: pulmonary vascular resistance ƒ Pulmonary vascular resistance (PVR) (PVR) ƒ 6-minute walk distance ƒ Secondary endpoint: 6-minute walk distance ƒ Invasive cardiopulmonary exercise test (iCPET) ƒ Cardiac magnetic resonance imaging 25


 
Upcoming Corporate Priorities HEMATOLOGY ƒ Luspatercept – Planned marketing authorization applications in US and EU for LR MDS and ɴ-thalassemia in 1H 2019 – MEDALIST and BELIEVE Phase 3 trial results planned to be submitted for publication in 2019 – COMMANDS Phase 3 clinical trial patient enrollment – Myelofibrosis Phase 2 trial preliminary topline results expected in 2H 2019 – BEYOND Phase 2 trial preliminary topline results expected in 2020 – Potential expansion of clinical program into other indications in 2019 NEUROMUSCULAR ƒ ACE-083 – FSHD/CMT Part 2 of the Phase 2 trials preliminary results expected (FSHD in 2H 2019/CMT by YE 2019) ƒ ACE-2494 – Phase 1 healthy volunteer trial results expected in 1H 2019 PULMONARY ƒ Sotatercept – Plan to initiate SPECTRA exploratory study in Q1 2019 – PULSAR Phase 2 trial preliminary results expected in 1H 2020 26


 
Long-term Vision for Growth and Value Creation ACE-083 (2019) Sotatercept (2020) • Phase 2 results expected in • PULSAR & SPECTRA Phase Luspatercept (2018) FSHD & CMT 2 results expected in PAH • Positive MEDALIST and BELIEVE Phase 3 trial results • COMMANDS and BEYOND trials initiated • Myelofibrosis Phase 2 trial ongoing Luspatercept (2019-2021) • MEDALIST/BELIEVE indication potential approvals in U.S. and E.U. • MF/BEYOND Phase 2 results expected • COMMANDS Phase 3 results expected • Potential expansion of clinical program into other indications Time 2018 Future 27


 
Additional Slides


 
ASH 2018: MEDALIST and BELIEVE Phase 3 Trial Results 29


 
MEDALIST Phase 3 Trial Design Double-blind Screening Week 24 Week 48 luspatercept 16-week Treated Lower- confirmed SC Primary Secondary Risk MDS transfusion Every 3 Endpoint Endpoint burden Weeks (RS+) Placebo 2:1 Randomized ƒ Primary Endpoint – RBC-ƚƌĂŶƐĨƵƐŝŽŶŝŶĚĞƉĞŶĚĞŶĐĞ;шϴǁĞĞŬƐͿĚƵƌŝŶŐƚŚĞĨŝƌƐƚϮϰǁĞĞŬƐ ƒ Secondary Endpoints – RBC-ƚƌĂŶƐĨƵƐŝŽŶŝŶĚĞƉĞŶĚĞŶĐĞ;шϴŽƌϭϮǁĞĞŬƐͿĚƵƌŝŶŐƚŚĞĨŝƌƐƚϰϴǁĞĞŬƐ – International Working Group hematologic improvement-erythroid (IWG HI-E) – Duration of transfusion independence (RBC-TI) 30 Trial ID: NCT02631070


 
MEDALIST Phase 3 Trial Primary ŶĚƉŽŝŶƚ͗ZĞĚůŽŽĚĞůůdƌĂŶƐĨƵƐŝŽŶ/ŶĚĞƉĞŶĚĞŶĐĞшϴtĞĞŬƐ Luspatercept Placebo RBC-d/шϴǁĞĞŬƐ (n = 153) (n = 76) Weeks 1–24, n (%) 58 (37.9) 10 (13.2) 95% CI 30.2–46.1 6.5–22.9 P valuea < 0.0001 a Cochran–Mantel–Haenszel test stratified for average baseline RBC transfusion requirement (ш 6 units vs < 6 units of RBCs/8 weeks) and baseline IPSS-R score (Very Low or Low vs Intermediate). CI, confidence interval. 31


 
MEDALIST Phase 3 Trial Secondary Endpoint: Erythroid Response (HI-E) Luspatercept Placebo (n = 153) (n = 76) Achieved HI-Ea (weeks 1–24), n (%) 81 (52.9) 9 (11.8) Reduction of ш4 RBC units/8 weeks (baseline transfusion burden ш4 units/8 weeks) 52/107 (48.6) 8/56 (14.3) ,ďŝŶĐƌĞĂƐĞŽĨшϭ͘ϱŐͬĚ> (baseline transfusion burden < 4 units/8 weeks) 29/46 (63.0) 1/20 (5.0) 95% CI 44.72–61.05 5.56–21.29 P valueb < 0.0001 a Defined as the proportion of patients meeting the HI-E criteria per IWG 2006 criteria (Cheson et al. 2006) sustained over a consecutive 56-day period during the indicated treatment period. b Luspatercept compared with placebo, Cochran–Mantel–Haenszel test. 32


 
BELIEVE Phase 3 Trial Design Double-blind Weeks Weeks Screening 13 - 24 37 - 48 12-week luspatercept Treated prospective ɴ-Thalassemia SC Primary Secondary pre- Every 3 Endpoint Transfusion- treatment Endpoint Weeks Dependent period Placebo 2:1 Randomized ƒ Primary Endpoint – шϯϯйƌĞĚƵĐƚŝŽŶŝŶƚƌĂŶƐĨƵƐŝŽŶďƵƌĚĞŶĨƌŽŵǁĞĞŬƐϭϯ-24 compared to pre-treatment period ƒ Key Secondary Endpoints – шϯϯйƌĞĚƵĐƚŝŽŶŝŶƚƌĂŶƐĨƵƐŝŽŶďƵƌĚĞŶĨƌŽŵǁĞĞŬƐϯϳ-48 compared to pre-treatment period – шϱϬйƌĞĚƵĐƚŝŽŶŝŶƚƌĂŶƐĨƵƐŝŽŶďƵƌĚĞŶĐŽŵƉĂƌĞĚƚŽƉƌĞ-treatment period – Mean change in transfusion burden from week 13 to week 24 33 Trial ID: NCT02604433


 
BELIEVE Phase 3 Trial Primary endpoint MET: Rate of Erythroid Response A significantly greater proportion of luspatercept-WUHDWHGSDWLHQWVDFKLHYHGD•UHGXFWLRQIURP baseline in transfusion burden during weeks 13 to 24 30 Luspatercept P < 0.0001 (OR 5.79, 95% CI 2.24–14.97) Placebo 25 20 15 21.4% (n = 48) 10 WĂƚŝĞŶƚƐĐŚŝĞǀŝŶŐшϯϯй Transfusion Burden ReductionBurden (%) Transfusion 5 4.5% (n = 5) 0 Luspatercept Placebo (n = 224) (n = 112) CI, confidence interval; OR, odds ratio. The BELIEVE Trial studied adult patients.


 
BELIEVE Phase 3 Trial All key secondary endpoints MET: Rates of Erythroid Response A significantly greater proportion of luspatercept-treated patients achieved clinically meaningful reductions in WUDQVIXVLRQEXUGHQRI•DQG• 30 Luspatercept P < 0.0001a 25 Placebo 20 P = 0.0017c 15 P = 0.0303b 10 19.6 Burden Reduction (%) Burden Reduction 5 10.3 Patients Achieving Transfusion Transfusion Achieving Patients 7.6 1.8 3.6 0.9 0 • • • (from week 37 to 48) (from week 13 to 24) (from week 37 to 48) • The least squares mean change in transfusion burden from baseline to weeks 13–24 (luspatercept versus placebo) ZDVí5%&XQLWVZHHNV &,íWRíP < 0.0001) a OR 6.44, 95% CI 2.27–18.26. b OR 4.55, 95% CI 1.03–20.11. c OR 11.92, 95% CI 1.65–86.29. The BELIEVE Trial studied adult patients.


 
BELIEVE Phase 3 Trial Reduction in transfusion burden during ANY 12- and 24-week interval During any 12- or 24-week interval, a significantly greater proportion of luspatercept-treated patients DFKLHYHGFOLQLFDOO\PHDQLQJIXOUHGXFWLRQVLQWUDQVIXVLRQEXUGHQRI•DQG• Any 12-week interval Any 24-week interval 100 100 Luspatercept P < 0.0001a Placebo 80 80 60 b 60 P < 0.0001 P < 0.0001c 40 40 P < 0.0001d 70.5 Burden Reduction (%) Burden Reduction Burden Reduction (%) Burden Reduction 20 40.2 20 41.1 16.5 Patients Achieving Transfusion Transfusion Achieving Patients 29.5 Transfusion Achieving Patients 6.3 2.7 0.9 0 0 • • • • a OR 5.69, 95% CI 3.46–9.35. b OR 9.95, 95% CI 4.44–22.33. c OR 25.02, 95% CI 7.76–80.71. d OR 20.37, 95% CI 2.86–144.94. The BELIEVE Trial studied adult patients.


 
COMMANDS Phase 3 Trial Design Open-label Screening luspatercept Weeks 0 - 24 Weeks 0 - 48 16-week (n = 175) Primary/ First-line, confirmed Secondary Secondary Lower- transfusion Endpoints Endpoints Risk MDS history epoetin alfa (n = 175) 1:1 Randomized ƒ Primary Endpoint – RBC-transfusion independence (RBC-TI) over the first 24 weeks ƒ Secondary Endpoints – International Working Group hematologic improvement-erythroid (IWG HI-E) – ш1.5 g/dL mean increase in hemoglobin over the first 24 weeks – Duration of RBC-TI and IWG HI-E 37 Trial ID: NCT03682536


 
BEYOND Phase 2 Trial Design Double-blind Screening luspatercept Weeks 13 - 24 Weeks 37 - 48 (n = 100) ɴ-Thalassemia 4-week Primary Secondary Non-Transfusion- period Endpoint Endpoint Dependent Placebo (n = 50) 2:1 Randomized ƒ Primary Endpoint – WƌŽƉŽƌƚŝŽŶŽĨƉĂƚŝĞŶƚƐǁͬĐŽŶƚŝŶƵŽƵƐŝŶĐƌĞĂƐĞшϭ͘ϬŐͬĚ>,ďĚƵƌŝŶŐǁĞĞŬƐϭϯƚŽϮϰ ƒ Key Secondary Endpoints – WƌŽƉŽƌƚŝŽŶŽĨƉĂƚŝĞŶƚƐǁͬĐŽŶƚŝŶƵŽƵƐŝŶĐƌĞĂƐĞшϭ͘ϬŐͬĚ>,ďƌĞƐƉŽŶĚĞƌƐǁĞĞŬƐϯϳƚŽϰϴ – Patient reported outcome measures: NTD-PRO / FACIT-F / SF-36 38 Trial ID: NCT03342404


 
Myelofibrosis Phase 2 Trial Design Luspatercept Monotherapy Cohort 1: Anemia Only (n = 20) 24 WEEKS ƒ ,ďчϵ͘ϱŐͬĚ>͕ŶŽZƚƌĂŶƐĨƵƐŝŽŶŝŶƉƌŝŽƌϴϰĚĂLJƐ Primary Endpoints Cohort 2: Transfusion Dependent (n = 20) ƒ Average of 2-4 RBC units / 4 weeks over 12 weeks Anemia Only Cohorts 1 & 3a: ƒ шнϭ͘ϱŐͬĚ>,ďĨŽƌшϭϮǁĞĞŬƐ;ƌŽůůŝŶŐͿ Luspatercept + Ruxolitinib Combo Transfusion Dependent Cohorts 2 & 3b: ƒ Zd/ĨŽƌшϭϮǁĞĞŬƐ;ƌŽůůŝŶŐͿ ŽŚŽƌƚϯĂ͗ŶĞŵŝĂKŶůLJ;ŶсчϭϱͿ ƒ ,ďчϵ͘ϱŐͬĚ>͕ŶŽZƚƌĂŶƐĨƵƐŝŽŶŝŶƉƌŝŽƌϴϰĚĂLJƐ ŽŚŽƌƚϯď͗dƌĂŶƐĨƵƐŝŽŶĞƉĞŶĚĞŶƚ;ŶсчϭϱͿ ƒ Average of 2-4 RBC units / 4 weeks over 12 weeks 39 Trial ID: NCT03194542